Foresite Capital Management III’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Foresite Capital Management III’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-62,245	Closed	-$2.12M	–	11
2020 Q1	$2.12M	Buy	+62,245	New	+$2.85M	3.37%	8
2019 Q4	–	Sell	-53,345	Closed	-$2.23M	–	14
2019 Q3	$2.23M	Sell	53,345 -11,904	-18%	-$503K	0.85%	14
2019 Q2	$2.86M	Sell	65,249 -11,130	-15%	-$627K	0.94%	17
2019 Q1	$3.93M	Sell	76,379 -29,327	-28%	-$1.27M	1.02%	17
2018 Q4	$3.91M	Hold	105,706	–	–	1.28%	15
2018 Q3	$3.97M	Hold	105,706	–	–	0.88%	20
2018 Q2	$4.18M	Hold	105,706	–	–	0.9%	17
2018 Q1	$2.72M	Hold	105,706	–	–	0.59%	18
2017 Q4	$2.85M	Buy	+105,706	New	+$2.91M	0.8%	15
2017 Q3	–	Sell	-30,000	Closed	-$750K	–	30
2017 Q2	$750K	Buy	+30,000	New	+$691K	0.25%	22

Other funds holding BHVN

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Foresite Capital Management III's BHVN Position: Q2 2020 in Review

Foresite Capital Management III sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2020, closing a stake of 62,245 shares — an estimated $2.12M sold.

Foresite Capital Management III first reported a position in BHVN in Q2 2017 and held it in 10 quarters. The position peaked at $4.18M in Q2 2018. 226 funds tracked by Wall St. Rank hold BHVN as of Q2 2020.

Foresite Capital Management III reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2020 after selling out during the quarter.
Foresite Capital Management III sold 62,245 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2020, an estimated $2.12M.
Foresite Capital Management III first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and held it in 10 quarters.
Foresite Capital Management III's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $4.18M in Q2 2018.
226 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2020.

Based on Foresite Capital Management III's 13F filing for Q2 2020, filed 13 Aug 2020.